Wedbush Weighs in on Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for Apellis Pharmaceuticals in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush currently has a “Neutral” rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. During the same quarter in the prior year, the firm earned ($1.50) earnings per share. Apellis Pharmaceuticals’s revenue was up 545.9% on a year-over-year basis.

Other analysts also recently issued research reports about the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Mizuho reissued a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the company from $68.00 to $80.00 in a report on Monday, February 5th. UBS Group lifted their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a report on Monday, March 4th. Finally, The Goldman Sachs Group lifted their price objective on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $47.53 on Thursday. The company has a 50 day moving average price of $59.71 and a 200-day moving average price of $57.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $94.75. The company has a market capitalization of $5.73 billion, a PE ratio of -10.61 and a beta of 0.88.

Insiders Place Their Bets

In other news, CAO James George Chopas sold 1,061 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total value of $68,965.00. Following the sale, the chief accounting officer now owns 39,067 shares of the company’s stock, valued at $2,539,355. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Adam J. Townsend sold 3,413 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total value of $221,845.00. Following the completion of the sale, the insider now owns 94,507 shares in the company, valued at $6,142,955. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO James George Chopas sold 1,061 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $68,965.00. Following the completion of the sale, the chief accounting officer now owns 39,067 shares of the company’s stock, valued at approximately $2,539,355. The disclosure for this sale can be found here. In the last three months, insiders have sold 406,651 shares of company stock valued at $25,130,257. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wynnefield Capital Inc. purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter worth about $380,000. General American Investors Co. Inc. purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter worth about $1,712,000. Profund Advisors LLC grew its holdings in Apellis Pharmaceuticals by 114.5% in the third quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock valued at $1,337,000 after purchasing an additional 18,766 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Apellis Pharmaceuticals by 6.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock valued at $33,451,000 after purchasing an additional 50,835 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).